Dominari Holdings Inc. quarterly report, Q2 FY2012

Business context and reporting period

Entity note: The supplied filing is Spherix Incorporated’s Form 10-Q, not a filing under the name Dominari Holdings Inc. It covers the quarter and six months ended June 30, 2012; financial statements are unaudited except the December 31, 2011 balance sheet.

Spherix operated Biospherics, which develops pharmaceutical products, and Health Sciences, which provides consulting services. All reported revenue in the first half came from Health Sciences; Biospherics generated no revenue.

Financial performance and position

Gross profit after direct costs was approximately $72,000 for the quarter and $172,000 for the half-year, representing gross margins of about 35% and 41%, respectively. At June 30, cash and cash equivalents were $4.20 million; working capital was $3.84 million; total assets were $4.57 million and total liabilities $0.68 million. The filing reports no debt balance. Cash used in operations was $1.77 million in the first half, and cash declined $0.71 million to $4.20 million.

Material changes versus prior comparable periods

• Second-quarter revenue increased about 11% year over year, while first-half revenue declined about 16%, which management attributed primarily to lower effective billing rates.
• Second-quarter net loss narrowed from $1.01 million to $0.75 million, including lower R&D expense following completion of SPX-106T preclinical studies. First-half net loss increased from $1.25 million to $1.90 million.
• The prior-year first-half results included $845,000 of gains on settlement of obligations and $53,000 of other income from government grants; neither was recorded in first-half 2012. These prior-period items explain much of the year-over-year increase in first-half net loss.
• February 2012 equity and warrant offering generated approximately $1.1 million net and added 1,064,816 common shares. Shares outstanding were 4,159,777 at June 30.

Outlook, risks and other notable items

• Management expected $3 million to $5 million of spending over the next 12 months for planned operations and said cash on hand should sustain operations through 2012. The estimate assumes continued development of SPX-106T, no significant renewed spending on D-tagatose as a diabetes drug, and additional financing to fund development beyond that period.
• The company expected continuing operating cash outflows and said it would need to raise funds consistently. It warned that inability to obtain financing could force it to stop development activities and dissolve. The existing shelf registration was expected to expire October 1, 2012, and the company said another significant offering under it was unlikely before expiration.
• An IND for SPX-106T was being prepared; a Phase 1a study could begin in fourth-quarter 2012 if FDA requirements were met, followed by a possible Phase 1b study in 2013. Management expected R&D costs to rise as clinical studies progressed and estimated three or more years to attract a development partner, with another two to four years for studies needed for an NDA filing.
• The company was pursuing other pipeline candidates, including SPX723T and programs for abdominal aortic aneurysms and interstitial cystitis/painful bladder syndrome. These were developmental plans, not established revenue sources.
• NASDAQ notified the company in April 2012 of a bid-price deficiency. Spherix sought shareholder approval for a reverse split intended to raise its stock price.
• Revenue and receivables were concentrated among a small number of customers/contracts. Four customers generated 79% of first-half 2012 revenue, and four contracts represented 67% of trade receivables at June 30. Cash exceeding FDIC insurance limits was reported at $3.9 million.
• A lease amendment extended the office lease to March 31, 2018; annual base rent from April 1, 2012 was $152,500, increasing 3% annually. Management reported disclosure controls effective at a reasonable assurance level and no material changes in internal controls during the quarter.

Important facts for investors to verify

1. Confirm the issuer identity: this source filing is for Spherix Incorporated, despite the request metadata naming Dominari Holdings Inc.
2. Assess whether financing can be raised after the shelf registration’s stated October 2012 expiration, and the resulting dilution and liquidity implications.
3. Track actual cash burn against management’s $3 million–$5 million 12-month spending estimate and its stated 2012 cash runway.
4. Verify FDA progress, clinical-trial timing and costs for SPX-106T, and whether additional development programs advance.
5. Review customer concentration, NASDAQ bid-price compliance and any subsequent material developments; the filing reported no significant subsequent events through issuance.